Drugs: Types, Classifications, Effects, and Addiction Risk

Types of drugs fall into seven pharmacologically distinct categories

These categories are defined by receptor mechanism, CNS effect, and addiction potential. Understanding what each drug class does to the brain and body is the first step toward recognizing substance use disorder and accessing effective treatment.

Key Takeaways

• The seven major drug categories are opioids, CNS depressants, stimulants, hallucinogens, cannabinoids, inhalants, and anabolic-androgenic steroids, each defined by a distinct neurochemical mechanism.
• According to the National Institute on Drug Abuse, approximately 23 percent of heroin users develop opioid use disorder, the highest use disorder rate of any commonly used substance.
• The DEA classifies controlled substances across five schedules based on abuse potential and accepted medical use, with Schedule I carrying no recognized medical application.
• CNS depressant withdrawal, including alcohol and benzodiazepine withdrawal, carries a mortality rate of up to 5 percent without medical supervision, making it among the most dangerous withdrawal syndromes.
• Fentanyl and fentanyl analogs accounted for over 73 percent of U.S. drug overdose deaths in 2022, according to the CDC.

What Are the Types of Drugs?

Types of drugs are substances that alter brain chemistry, CNS function, or physiological processes, classified by their receptor targets, mechanisms of action, and effects on mood, cognition, and behavior.

How Drugs Are Defined Pharmacologically

The pharmacological definition of a drug focuses on receptor binding and mechanism rather than legal status or social context:

• A drug is any substance that produces a physiological or psychological effect by interacting with biological receptors, enzymes, or ion channels in the body.
• Psychoactive drugs specifically target the central nervous system, altering neurotransmitter activity in ways that affect mood, perception, cognition, or motor function.
• Not all psychoactive substances produce physical dependence, but all substances associated with substance use disorder generate neurochemical changes in the mesolimbic reward system.

Why Drug Classification Matters Clinically

Accurate drug classification determines treatment protocol, withdrawal management strategy, and overdose response:

• Drug category determines which withdrawal syndrome a patient will experience and whether that syndrome carries life-threatening risk requiring medical supervision.
• Understanding drug class helps clinicians select appropriate pharmacological interventions, including naloxone for opioid overdose and benzodiazepines for alcohol withdrawal seizure prevention.
• DSM-5-TR substance use disorder diagnoses are organized by drug category, meaning accurate classification is foundational to correct diagnosis and treatment planning.

How Different Drug Types Affect the Brain

All addictive substances produce their reinforcing effects by elevating dopamine activity in the mesolimbic reward pathway, the brain circuit connecting the ventral tegmental area to the nucleus accumbens and prefrontal cortex.

The Mesolimbic Dopamine Pathway

The mesolimbic pathway is the central neurobiological substrate of addiction across all drug categories:

• All addictive substances converge on the nucleus accumbens by elevating dopamine either directly through reuptake blockade and release, or indirectly by disinhibiting dopaminergic neurons through GABA suppression.
• According to the National Institute on Drug Abuse, cocaine and methamphetamine elevate nucleus accumbens dopamine up to 1,000 percent above baseline, overwhelming the brain’s natural reward system and driving compulsive substance use.
• The mesolimbic pathway controls motivation, reinforcement learning, and habit formation, which is why drug-associated cues continue to trigger cravings long after acute withdrawal resolves.

Neuroadaptation and Physical Dependence

Repeated drug exposure triggers neuroadaptive changes that sustain compulsive use beyond the initial reward phase:

• Receptor downregulation occurs when the brain reduces receptor density or sensitivity in response to chronic drug exposure, generating tolerance and making baseline dopaminergic reward insufficient for normal function.
• Physical dependence develops when neuroadaptation produces a withdrawal syndrome upon drug discontinuation, reflecting the brain’s attempt to restore homeostasis in the absence of the substance.
• Post-acute withdrawal syndrome extends neurobiological vulnerability for opioids, benzodiazepines, and alcohol for 6 to 24 months beyond acute detox through persistent mood dysregulation and cravings linked to incomplete receptor resensitization.

Drug Classification Systems: Pharmacological, Chemical, and Legal

Drug classification systems organize substances by mechanism, molecular structure, or legal status, with each framework serving a distinct clinical, research, or regulatory purpose.

Pharmacological Classification

The pharmacological framework groups drugs by the receptor systems they target and the CNS effects they produce:

• Pharmacological classification divides drugs into opioids, CNS depressants, stimulants, hallucinogens, cannabinoids, inhalants, and anabolic-androgenic steroids based on the primary receptor mechanism driving their effects.
• This framework is the most clinically useful because it directly predicts withdrawal syndrome severity, overdose presentation, and appropriate pharmacological treatment.
• A single drug can activate multiple receptor systems simultaneously, as alcohol does through both GABA-A potentiation and NMDA glutamate receptor antagonism, compounding both its CNS effects and its withdrawal danger.

Legal Classification: DEA Schedules

The DEA Controlled Substances Act organizes drugs into five schedules based on abuse potential and accepted medical use:

• Schedule I substances including heroin, psilocybin, and LSD are classified as having no accepted medical use and high abuse potential, making them illegal to prescribe or dispense.
• Schedule II substances including fentanyl, methamphetamine, and cocaine carry the highest abuse potential among substances with accepted medical applications and require the most stringent prescribing controls.
• Schedules III through V reflect progressively lower abuse potential and broader clinical applications, with Schedule V substances such as low-dose codeine preparations carrying the least restrictive dispensing requirements.

Chemical Classification

The chemical classification framework groups substances by molecular structure and is primarily used in forensic toxicology and regulatory contexts:

• Chemically related compounds frequently produce similar pharmacological effects, which is why synthetic opioid analogs carry predictable mu-opioid receptor activity despite differing molecularly from their parent compounds.
• Chemical classification underlies analogue drug scheduling, which allows the DEA to classify newly synthesized designer drugs as controlled substances when their molecular structure substantially resembles an already-scheduled compound.
• The clinical relevance of chemical classification in addiction medicine is that it helps clinicians anticipate cross-tolerance between structurally similar drugs, a factor that directly informs medication-assisted treatment dosing decisions.

The 7 Major Drug Categories and Their Effects

The seven major drug categories each produce distinct receptor-level effects, withdrawal profiles, and overdose risks that determine how substance use disorder develops and how it is treated.

1- Opioids

Opioids bind to mu, kappa, and delta opioid receptors distributed throughout the brain, spinal cord, and gastrointestinal tract, producing analgesia, euphoria, and respiratory depression with receptor selectivity that varies across compounds.

High-potency and illicit opioid compounds carry the following pharmacological profiles:

• Heroin converts to 6-monoacetylmorphine within seconds of intravenous administration, crossing the blood-brain barrier more rapidly than morphine due to its higher lipophilicity and generating the characteristic rush that reinforces compulsive redosing.
• Fentanyl carries 80 to 100 times the potency of morphine at the mu-opioid receptor and now drives the majority of opioid overdose mortality in the United States.
• Black tar heroin delivers potent mu-opioid receptor activation but carries elevated infection risk due to acetylating agent residues and solvent impurities.

Supply-side contamination and novel adulterants introduce the following clinical risks:

• The contamination of the illicit drug supply with fentanyl-laced substances has made opioid use disorder acutely lethal regardless of the drug a person intends to use.
• Tranq dope, a combination of fentanyl and xylazine, produces deep sedation and necrotic wounds that naloxone cannot reverse because xylazine acts through alpha-2 adrenergic receptors rather than opioid receptors.

Prescription opioid compounds most commonly associated with misuse include:

• Oxycodone produces analgesia and euphoria through selective mu-opioid receptor agonism and remains among the most commonly misused prescription opioids, with detection windows in urine that vary based on dose, frequency, and metabolic rate.
• Lean, a mixture of codeine-containing promethazine cough syrup and soda, produces opioid sedation through codeine’s CYP2D6-mediated hepatic conversion to morphine, with effects highly variable based on individual metabolizer phenotype.

Opioid-induced sedation carries the following clinical significance:

• Nodding off, the colloquial term for opioid-induced sedation, reflects mu-opioid receptor-mediated suppression of the ascending reticular arousal system and indicates a dose approaching respiratory depression threshold.

2- Central Nervous System Depressants

Central nervous system depressants reduce neuronal excitability by potentiating GABA-mediated inhibitory transmission or blocking excitatory glutamate activity at NMDA receptors, producing sedation, anxiolysis, muscle relaxation, and respiratory depression at supratherapeutic doses.

Distinct mechanisms of GABA-A potentiation characterize the two primary CNS depressant classes:

• Benzodiazepines act as positive allosteric modulators at the GABA-A receptor chloride ionophore complex, increasing chloride channel opening frequency in the presence of endogenous GABA without directly activating the receptor.
• Alcohol potentiates GABA-A receptor activity through a distinct allosteric binding site and simultaneously suppresses NMDA glutamate receptors, generating CNS depression through two independent mechanisms that compound each other’s lethality.

Pharmacokinetic differences among benzodiazepines produce the following clinical distinctions:

• Alprazolam generates pronounced interdose withdrawal between scheduled doses due to its short half-life and high receptor affinity, accelerating physical dependence more rapidly than longer-acting benzodiazepines.
• Clonazepam produces a gradual onset and extended duration of effect, making it pharmacologically preferred for benzodiazepine withdrawal taper protocols where stable blood levels reduce seizure risk.

Polydrug combinations involving CNS depressants carry the following compounded risks:

• Combining alcohol with benzodiazepines produces synergistic CNS depression capable of suppressing respiration at doses neither substance would cause in isolation.
• Drinking alcohol while taking fluoxetine combines ethanol-mediated GABA-A potentiation with serotonin transporter inhibition, producing unpredictable mood instability and cognitive impairment that neither substance causes independently.

Post-detoxification neurobiological adaptations include the following recovery vulnerabilities:

• Dry drunk syndrome describes the persistence of emotional dysregulation and behavioral patterns from active alcohol use disorder in individuals who have achieved abstinence, demonstrating that neurobiological adaptation to chronic alcohol exposure outlasts physical detoxification.
• Alcohol detox disrupts sleep architecture by suppressing REM cycles, and post-detoxification insomnia persisting for weeks to months represents a primary relapse vulnerability in alcohol use disorder recovery.
• The concept of California sober, which substitutes cannabis or psychedelics for alcohol, lacks clinical evidence supporting it as a sustained recovery framework per addiction medicine literature.

3- Stimulants

Stimulants elevate CNS activity by blocking monoamine reuptake transporters or triggering mass release of dopamine, norepinephrine, and serotonin into synaptic clefts, producing arousal, appetite suppression, tachycardia, and intense reinforcing euphoria.

Primary stimulant compounds produce neurochemical effects through the following mechanisms:

• Cocaine blocks the dopamine transporter, norepinephrine transporter, and serotonin transporter simultaneously, generating cardiovascular stimulation that elevates myocardial infarction risk alongside the mesolimbic dopamine surge that drives stimulant use disorder.
• Methamphetamine reverses the dopamine transporter to actively flood synapses with dopamine reserves rather than simply preventing reuptake, which explains its greater neurotoxicity and more prolonged dopaminergic dysregulation compared to cocaine.

Long-term stimulant exposure generates the following neurobiological consequences:

• Chronic methamphetamine use depletes striatal dopamine transporter density by up to 50 percent, according to NIDA, generating anhedonia and prolonged dysphoria that makes early stimulant use disorder recovery acutely vulnerable to relapse.
• Cocaine’s vasoconstrictive properties progressively damage nasal tissue, septal cartilage, and mucosal architecture through ischemic necrosis that worsens with continued insufflation.

4- Hallucinogens

Hallucinogens alter perception, cognition, and sensory processing through two pharmacologically distinct mechanisms: serotonergic agonism for classic hallucinogens and glutamate receptor antagonism for dissociatives.

Classic and dissociative hallucinogens act through the following distinct receptor pathways:

• Classic hallucinogens including psilocybin, LSD, and DMT act as partial agonists at 5-HT2A serotonin receptors in the prefrontal cortex and thalamus, disrupting thalamocortical sensory gating and generating visual distortions, synesthesia, and profound alterations in time perception.
• Dissociative hallucinogens including ketamine, PCP, and high-dose dextromethorphan produce perceptual alterations through NMDA glutamate receptor antagonism, generating ego dissolution and out-of-body experiences with a distinct clinical presentation.

Hallucinogen dependence and disorder present the following clinical considerations:

• Neither classic hallucinogens nor dissociatives generate the physical withdrawal syndrome that defines opioid, benzodiazepine, or alcohol dependence, though hallucinogen persisting perception disorder and psychological dependence represent clinically significant treatment considerations.
• The DSM-5-TR classifies hallucinogen use disorder as a diagnosable substance use disorder when hallucinogen use produces significant functional impairment despite continued use.

5- Cannabinoids

Cannabis contains over 100 cannabinoid compounds, with delta-9-tetrahydrocannabinol producing primary psychoactive effects through partial agonism at CB1 receptors in the basal ganglia, hippocampus, and prefrontal cortex.

Chronic cannabis use produces the following neuroadaptive changes and withdrawal profile:

• Chronic daily cannabis use produces CB1 receptor downregulation, generating cannabis withdrawal syndrome upon abrupt discontinuation that includes irritability, insomnia, appetite suppression, and anxiety meeting DSM-5-TR diagnostic criteria.
• Cannabis use disorder affects approximately 9 percent of those who use cannabis, rising to 17 percent among those who begin use during adolescence, according to NIDA.

High-potency cannabis concentrate products carry the following accelerated risk profile:

• High-potency cannabis concentrates including wax, shatter, and live resin deliver THC concentrations of 60 to 90 percent compared to 15 to 25 percent in traditional flower, substantially accelerating the rate and severity of cannabis use disorder development.

6- Inhalants

Inhalants are volatile substances including hydrocarbons, nitrous oxide, and aerosol propellants that produce rapid CNS effects through direct pulmonary absorption into systemic circulation, bypassing the hepatic first-pass metabolism that attenuates oral drug bioavailability.

Inhalant compounds produce CNS effects through the following mechanisms and acute risks:

• They generate psychoactive effects through GABA-A potentiation, NMDA antagonism, and direct neurotoxicity, and the acute intoxication window of 15 to 30 minutes encourages repeated dosing that increases the risk of sudden sniffing death syndrome through ventricular arrhythmia.

Chronic inhalant exposure produces the following long-term neurological consequences:

• Chronic inhalant exposure produces white matter demyelination in frontal and cerebellar regions, generating persistent cognitive deficits that compound the psychiatric vulnerabilities driving continued inhalant use disorder.

7- Anabolic-Androgenic Steroids

Anabolic-androgenic steroids produce their primary effects through androgen receptor activation in skeletal muscle, bone, and neural tissue, generating protein synthesis, lean mass accretion, and in the CNS, mood dysregulation and aggressive behavioral activation.

Discontinuation of anabolic-androgenic steroids triggers the following neuroendocrine consequences:

• Abrupt anabolic-androgenic steroid discontinuation suppresses the hypothalamic-pituitary-gonadal axis, producing hypogonadism, anhedonia, and major depressive episode symptoms that can persist for months post-cessation without pharmacological hormonal support.

Diagnostic classification of anabolic-androgenic steroid use disorder includes the following criteria:

• The DSM-5-TR classifies anabolic-androgenic steroid use disorder within the substance-related and addictive disorders chapter, recognizing compulsive use as a diagnosable condition despite its mechanistic differences from classical CNS-active drugs.

Addiction Risk, Overdose Danger, and Long-Term Consequences by Drug Type

Addiction risk, overdose danger, and long-term health consequences vary significantly across drug types based on receptor mechanism, speed of neuroadaptation, and the presence or absence of a life-threatening withdrawal syndrome.

Most Addictive Drug Categories

The most pharmacologically reinforcing substances based on animal self-administration paradigms and human epidemiological data include:

• Heroin, cocaine, methamphetamine, alcohol, and nicotine consistently rank highest in reinforcement potential, reflecting the speed and magnitude of mesolimbic dopamine activation relative to the brain’s baseline reward threshold.
• According to NIDA, approximately 23 percent of heroin users develop opioid use disorder, compared to approximately 15 percent of cocaine users and 9 percent of cannabis users.

Physical dependence through receptor downregulation drives compulsive drug-seeking through the following mechanisms:

• Receptor downregulation makes abstinence physically intolerable rather than merely psychologically uncomfortable, sustaining drug-seeking behavior independently of psychological craving.
• Recognizing and managing relapse risk factors, including environmental cues, emotional dysregulation, and social triggers, is essential during the extended neurobiological vulnerability period that follows acute detoxification.
• Post-acute withdrawal syndrome extends this vulnerability for opioids, benzodiazepines, and alcohol through mood instability, cognitive slowing, and cravings that persist for 6 to 24 months beyond acute detox.

Overdose Risk and Emergency Warning Signs

Overdose risk correlates primarily with CNS depressant properties, dosing variability in the illicit drug supply, and individual tolerance fluctuation following even brief abstinence.

The following signs require an immediate 911 response:

• Respirations below 12 per minute or completely absent.
• Blue, gray, or purple discoloration of lips or fingernails indicating cyanosis.
• Unresponsive to voice or painful stimulus.
• Gurgling or snoring sounds indicating airway obstruction.
• Seizure activity in a person known to use CNS depressants or alcohol.
• Rigid or completely limp muscle tone combined with unresponsiveness.

Opioid overdose reversal and contaminated supply carry the following response considerations:

• Opioid overdose presents with respiratory depression, miosis, and loss of consciousness, and naloxone reverses opioid-mediated respiratory suppression by displacing opioids from mu-opioid receptors through competitive antagonism.
• Fentanyl-laced substances and xylazine contamination complicate overdose response because xylazine-associated sedation requires airway management and supportive care beyond naloxone administration.

CNS depressant overdose carries the following distinct management requirements:

• Alcohol and benzodiazepine overdose require hemodynamic stabilization and airway protection because no specific antidote reverses GABA-A-mediated CNS depression with the reliability that naloxone achieves at opioid receptors.

Long-Term Health Consequences by Drug Class

Chronic substance use disorder produces organ-level and neurological damage that persists well beyond the period of active use and requires integrated medical and psychiatric management.

Chronic opioid use disorder generates the following long-term physiological consequences:

• Chronic opioid use disorder produces opioid-induced hyperalgesia, a paradoxical increase in pain sensitivity resulting from mu-opioid receptor downregulation and neuroinflammatory changes in spinal pain processing circuits.

Chronic alcohol use disorder produces the following multi-system complications:

• Chronic alcohol use disorder generates hepatic fibrosis and cirrhosis through acetaldehyde-mediated hepatocyte damage, peripheral neuropathy through thiamine depletion, and Wernicke-Korsakoff syndrome in cases of severe nutritional deficiency.

Chronic stimulant use disorder produces the following neuropsychiatric consequences:

• Methamphetamine-associated psychosis develops in approximately 40 percent of chronic users and in some cases persists as a primary psychotic disorder independent of continued drug use.

Protracted withdrawal and early recovery vulnerabilities include the following:

• Protracted benzodiazepine withdrawal syndrome produces anxiety, cognitive impairment, and sensory disturbances that outlast acute withdrawal by months to years in a clinically significant subset of users.
• Reducing screen time and digital stimulation during early recovery supports dopaminergic system restoration by removing a secondary source of variable-ratio reinforcement that competes neurologically with natural reward processing.
• Navigating intimate relationships during early recovery requires active attention to co-occurring attachment patterns and relational triggers that independently sustain substance use disorder relapse cycles.

Treatment at New Spirit Recovery

New Spirit Recovery provides medically supervised care for all seven drug categories across California facilities, with treatment matched to each patient’s drug class, withdrawal risk, and co-occurring mental health diagnosis.

Medical Detox

Medically supervised detox at New Spirit Recovery manages acute withdrawal safely across all drug categories using ASAM-compliant clinical protocols:

• Opioid withdrawal is managed using COWS-guided assessment and medication-assisted treatment protocols, preventing the neurobiological cascade that drives early relapse during the acute detox window.
• CNS depressant withdrawal, including alcohol and benzodiazepine withdrawal, is managed with monitored taper protocols that eliminate seizure risk and life-threatening withdrawal complications.
• 24-hour nursing coverage and physician oversight throughout detox ensures that escalating withdrawal severity is identified and treated before it becomes medically dangerous.

Residential Treatment

Residential treatment provides structured daily programming while patients stabilize neurologically following acute detox:

• Daily programming includes CBT groups, DBT skills training, relapse prevention work, psychoeducation, somatic therapy, and the proprietary Rewired curriculum developed by New Spirit co-founder Erica Spiegelman.
• Six daily programming hours, seven days per week, builds the behavioral and cognitive skills needed to manage the extended neurobiological vulnerability of post-acute withdrawal syndrome.
• Continuity between the detox and residential phases ensures that the same clinical team tracks each patient’s progress without the treatment fragmentation that increases relapse risk during transitions.

Dual Diagnosis Treatment

Dual diagnosis care addresses the co-occurring mental health conditions that drive substance use across all drug categories:

• New Spirit’s clinical team provides simultaneous treatment of both the substance use disorder and the co-occurring psychiatric condition, rather than sequential treatment that delays mental health intervention.
• Trauma-focused therapies including EMDR are available for patients whose substance use disorder is linked to unresolved trauma, a pattern common across opioid, CNS depressant, and stimulant use disorder presentations.
• Psychiatric medication management for co-occurring conditions including major depressive disorder, anxiety disorders, PTSD, and bipolar disorder is integrated into the treatment plan from admission.

Medication-Assisted Treatment

Medication-assisted treatment supports recovery from opioid and alcohol use disorder using FDA-approved pharmacotherapy:

• Buprenorphine-naloxone, naltrexone, and Vivitrol are available as clinically appropriate, with medication selection guided by the patient’s drug category, use history, and co-occurring medical conditions.
• MAT continuation through residential and step-down programming levels maintains neurochemical stability during the period of highest relapse vulnerability.
• MAT is delivered within a comprehensive therapeutic framework that addresses the behavioral and psychological dimensions of substance use disorder alongside the pharmacological component.

Step-Down Programming

Step-down programming through PHP, IOP, and outpatient levels sustains recovery momentum after residential treatment:

• Progressive reduction in programming intensity allows patients to reintegrate into daily responsibilities while maintaining clinical support during the extended neurobiological recovery window.
• PHP and IOP programming continues the evidence-based modalities from residential treatment, including CBT, DBT, and relapse prevention groups, at a frequency matched to each patient’s stabilization level.
• Same-day assessments are available for patients at any level of care who need immediate clinical evaluation.

Veterans Program

The veterans program provides specialized care for military service members and veterans with substance use disorder:

• Veteran-specific programming addresses military trauma, PTSD-linked substance use patterns, and the unique treatment barriers that veterans face in civilian treatment settings.
• Green Beret specialists provide additional weekly sessions tailored to military trauma, combat-related PTSD triggers, and veteran-specific relapse risk factors.
• VA CCN and TriWest insurance contracts are accepted, and the admissions team coordinates benefits verification for eligible veterans.

Family Services

Family services support the recovery of both the patient and the family system affected by substance use disorder:

• Family therapy is available throughout the treatment stay, addressing co-dependent relationship patterns, communication skills, and boundary-setting that sustains the patient’s recovery after discharge.
• Family education provides clear clinical information about the neurobiology of addiction, the withdrawal timeline, and the extended recovery period, reducing family behaviors that inadvertently undermine treatment.
• Discharge planning includes referrals for family members to Al-Anon and peer support resources that sustain systemic changes initiated during treatment.

Frequently Asked Questions

What are the 7 types of drugs?

The seven major drug types are opioids, CNS depressants, stimulants, hallucinogens, cannabinoids, inhalants, and anabolic-androgenic steroids, each defined by a distinct receptor mechanism and CNS effect profile that determines its addiction potential and withdrawal risk.

What drug has the highest addiction potential?

Heroin carries the highest use disorder development rate of commonly used substances at approximately 23 percent, according to NIDA, followed by cocaine at 15 percent and cannabis at 9 percent, reflecting the speed and magnitude of mesolimbic dopamine activation each produces.

What is the most dangerous drug withdrawal?

CNS depressant withdrawal, including alcohol and benzodiazepine withdrawal, is medically the most dangerous, carrying a mortality rate of up to 5 percent without medical supervision due to the risk of grand mal seizures and cardiovascular instability that opioid withdrawal does not produce.

What is the difference between Schedule I and Schedule II drugs?

Schedule I substances have no accepted medical use and a high potential for abuse, while Schedule II substances have accepted medical applications but carry the highest abuse potential among prescribable drugs, including fentanyl, methamphetamine, and cocaine.

What is post-acute withdrawal syndrome?

Post-acute withdrawal syndrome is a prolonged neurobiological recovery period following acute detox in which mood instability, cognitive slowing, and cravings persist for 6 to 24 months, primarily affecting patients recovering from opioid, benzodiazepine, and alcohol use disorder.

Can cannabis use cause withdrawal?

Yes, cannabis withdrawal is a DSM-5-TR recognized syndrome that occurs upon abrupt discontinuation of chronic daily use, producing irritability, insomnia, appetite suppression, and anxiety that typically peak within the first week of abstinence.

Does hallucinogen use disorder require physical withdrawal to be diagnosed?

No, hallucinogen use disorder is diagnosed when hallucinogen use produces significant functional impairment despite continued use, regardless of whether physical withdrawal is present, because the DSM-5-TR recognizes compulsive use and functional decline as sufficient diagnostic criteria independent of withdrawal syndrome.

References

1. National Institute on Drug Abuse. (2020). Drugs, Brains, and Behavior: The Science of Addiction. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction
2. National Institute on Drug Abuse. (2021). Opioid Overdose Crisis. https://nida.nih.gov/research-topics/opioids/opioid-overdose-crisis
3. Centers for Disease Control and Prevention. (2023). Drug Overdose Deaths in the United States, 2002–2022. https://www.cdc.gov/nchs/products/databriefs/db491.htm
4. Drug Enforcement Administration. (2023). Drug Scheduling. https://www.dea.gov/drug-information/drug-scheduling
5. Substance Abuse and Mental Health Services Administration. (2023). Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. https://www.samhsa.gov/data/
6. National Institute on Drug Abuse. (2020). Cannabis (Marijuana) Research Report. https://nida.nih.gov/publications/research-reports/marijuana/what-are-marijuana-effects
7. National Institute on Alcohol Abuse and Alcoholism. (2021). Alcohol Use Disorder: Comparison Between DSM-IV and DSM-5. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm
8. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.